Literature DB >> 3533883

The renaissance of erythromycin.

A S Malmborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3533883     DOI： 10.1093/jac/18.3.293

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

3.  Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

4.  Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base.

Authors:  P Villa; D Sassella; M Corada; I Bartosek
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 5.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 6.  Adverse effects of macrolide antibacterials.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

7.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

8.  New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance.

Authors:  P B Fernandes; W R Baker; L A Freiberg; D J Hardy; E J McDonald
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.